ATE448222T1 - 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe - Google Patents
2,4-dioxo-3-chinazolinylarylsulfonylharnstoffeInfo
- Publication number
- ATE448222T1 ATE448222T1 AT04789522T AT04789522T ATE448222T1 AT E448222 T1 ATE448222 T1 AT E448222T1 AT 04789522 T AT04789522 T AT 04789522T AT 04789522 T AT04789522 T AT 04789522T AT E448222 T1 ATE448222 T1 AT E448222T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- sup
- group
- alkyl
- member selected
- Prior art date
Links
- 150000003672 ureas Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 208000007536 Thrombosis Diseases 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000005647 linker group Chemical group 0.000 abstract 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50856403P | 2003-10-03 | 2003-10-03 | |
| PCT/US2004/032921 WO2005032488A2 (en) | 2003-10-03 | 2004-09-29 | 2,4-dioxo-3-quinazolinylaryl sulfonylureas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE448222T1 true ATE448222T1 (de) | 2009-11-15 |
Family
ID=34421757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04789522T ATE448222T1 (de) | 2003-10-03 | 2004-09-29 | 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7109332B2 (de) |
| EP (1) | EP1668002B1 (de) |
| JP (1) | JP2007507551A (de) |
| KR (1) | KR20060113700A (de) |
| CN (1) | CN1863798B (de) |
| AT (1) | ATE448222T1 (de) |
| AU (1) | AU2004278030C1 (de) |
| CA (1) | CA2540214A1 (de) |
| DE (1) | DE602004024093D1 (de) |
| ES (1) | ES2334795T3 (de) |
| IL (1) | IL174446A (de) |
| MX (1) | MXPA06003618A (de) |
| PL (1) | PL1668002T3 (de) |
| PT (1) | PT1668002E (de) |
| WO (1) | WO2005032488A2 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0418026A (pt) * | 2003-12-22 | 2007-04-17 | Ajinomoto Kk | derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças |
| WO2006039212A2 (en) * | 2004-09-29 | 2006-04-13 | Portola Pharmaceuticals, Inc. | Substituted 2h-1,3-benzoxazin-4(3h)-ones |
| CA2627719C (en) * | 2005-11-03 | 2016-07-12 | Portola Pharmaceuticals, Inc. | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
| US7834023B2 (en) | 2006-09-20 | 2010-11-16 | Portola Pharmaceuticals, Inc. | Substituted dihydroquinazolines as platelet ADP receptor inhibitors |
| CA2682207A1 (en) * | 2007-04-05 | 2008-10-16 | Cv Therapeutics, Inc. | Quinazolinone derivatives as aldh-2 inhibitors |
| WO2008133155A1 (ja) | 2007-04-19 | 2008-11-06 | Astellas Pharma Inc. | 二環式ヘテロ環化合物 |
| CA2686221A1 (en) * | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
| CN101654441B (zh) * | 2008-08-19 | 2012-10-03 | 信谊药厂 | 抗凝化合物、组合物及其用途 |
| RU2538965C2 (ru) | 2009-01-19 | 2015-01-10 | Эббви Инк. | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний |
| NZ616828A (en) | 2009-01-19 | 2015-03-27 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| MX2014005304A (es) | 2011-10-31 | 2015-03-20 | Xenon Pharmaceuticals Inc | Biaril eter sulfonamidas y su uso como agentes terapeuticos. |
| ES2586213T3 (es) | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| CA2874621A1 (en) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
| US10071957B2 (en) | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| CN105263490B (zh) | 2013-03-14 | 2018-05-22 | 基因泰克公司 | 取代的三唑并吡啶及其使用方法 |
| CA2898680A1 (en) | 2013-03-15 | 2014-09-18 | Genentech,Inc. | Substituted benzoxazoles and methods of use thereof |
| JP6383418B2 (ja) | 2013-11-27 | 2018-08-29 | ジェネンテック， インコーポレイテッド | 置換ベンズアミド及びその使用方法 |
| CN106715418A (zh) | 2014-07-07 | 2017-05-24 | 基因泰克公司 | 治疗化合物及其使用方法 |
| JP6929792B2 (ja) | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| MA42118A (fr) | 2015-05-22 | 2018-03-28 | Genentech Inc | Benzamides substitués et leurs méthodes d'utilisation |
| WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| JP6987746B2 (ja) | 2015-09-28 | 2022-01-05 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| US10899732B2 (en) | 2015-11-25 | 2021-01-26 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| US10766858B2 (en) | 2016-03-30 | 2020-09-08 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| BR112019007763A2 (pt) | 2016-10-17 | 2019-07-02 | Genentech Inc | composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção |
| EP3601273B1 (de) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamid-derivate als natriumkanalinhibitoren |
| CN110914256A (zh) | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| WO2019191702A1 (en) | 2018-03-30 | 2019-10-03 | F. Hoffmann-La Roche Ag | Substituted hydro-pyrido-azines as sodium channel inhibitors |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| CA3116141C (en) | 2018-12-06 | 2023-09-05 | Daiichi Sankyo Company, Limited | Cycloalkane-1,3-diamine derivative |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9702774D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| CA2318199A1 (en) | 1998-01-15 | 1999-07-22 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
| WO2001057037A1 (en) * | 2000-02-04 | 2001-08-09 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
| US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
-
2004
- 2004-09-29 PL PL04789522T patent/PL1668002T3/pl unknown
- 2004-09-29 CN CN2004800287913A patent/CN1863798B/zh not_active Expired - Fee Related
- 2004-09-29 MX MXPA06003618A patent/MXPA06003618A/es active IP Right Grant
- 2004-09-29 EP EP04789522A patent/EP1668002B1/de not_active Expired - Lifetime
- 2004-09-29 ES ES04789522T patent/ES2334795T3/es not_active Expired - Lifetime
- 2004-09-29 CA CA002540214A patent/CA2540214A1/en not_active Abandoned
- 2004-09-29 AU AU2004278030A patent/AU2004278030C1/en not_active Ceased
- 2004-09-29 AT AT04789522T patent/ATE448222T1/de active
- 2004-09-29 US US10/956,004 patent/US7109332B2/en not_active Expired - Fee Related
- 2004-09-29 KR KR1020067008644A patent/KR20060113700A/ko not_active Ceased
- 2004-09-29 PT PT04789522T patent/PT1668002E/pt unknown
- 2004-09-29 JP JP2006534290A patent/JP2007507551A/ja active Pending
- 2004-09-29 DE DE602004024093T patent/DE602004024093D1/de not_active Expired - Lifetime
- 2004-09-29 WO PCT/US2004/032921 patent/WO2005032488A2/en not_active Ceased
-
2006
- 2006-03-21 IL IL174446A patent/IL174446A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005032488A2 (en) | 2005-04-14 |
| WO2005032488A3 (en) | 2005-05-12 |
| IL174446A (en) | 2012-02-29 |
| MXPA06003618A (es) | 2006-08-11 |
| DE602004024093D1 (de) | 2009-12-24 |
| CN1863798B (zh) | 2011-08-31 |
| EP1668002A2 (de) | 2006-06-14 |
| KR20060113700A (ko) | 2006-11-02 |
| US7109332B2 (en) | 2006-09-19 |
| PT1668002E (pt) | 2009-11-25 |
| AU2004278030B2 (en) | 2010-07-01 |
| AU2004278030C1 (en) | 2010-12-02 |
| CN1863798A (zh) | 2006-11-15 |
| HK1093973A1 (en) | 2007-03-16 |
| ES2334795T3 (es) | 2010-03-16 |
| JP2007507551A (ja) | 2007-03-29 |
| EP1668002A4 (de) | 2006-12-20 |
| US20050107357A1 (en) | 2005-05-19 |
| EP1668002B1 (de) | 2009-11-11 |
| PL1668002T3 (pl) | 2010-02-26 |
| AU2004278030A1 (en) | 2005-04-14 |
| CA2540214A1 (en) | 2005-04-14 |
| IL174446A0 (en) | 2006-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004024093D1 (de) | 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe | |
| ATE449099T1 (de) | Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren | |
| MXPA04004457A (es) | Novedosos derivados de 1,2,4-tiadiazolio como moduladores del receptor de melanocortina. | |
| BG104248A (en) | Benzamidoxim derivatives, intermediate products and methods for preparing and using them as fungicides | |
| GR3034398T3 (en) | 2-[1',2',4'-triazol-3'-yloxymethylene]-anilides and their use as pest-control agents | |
| DE60221098D1 (de) | Kondensierte heterocyclische derivate | |
| EA200300621A1 (ru) | Биарильные производные никотинамида, полезные в качестве ингибиторов изоферментов pde4 | |
| WO1999033858A3 (en) | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use | |
| WO2007071632A3 (en) | 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases | |
| WO2004004730A3 (en) | 2-aminopyrazine derivatives as inhibitors of cyclin dependent kinases for the treatment of proliferative disorders | |
| EA200401470A1 (ru) | Производные пиперазинилацилпиперидина, их получение и их терапевтическое применение | |
| MY146599A (en) | New azetidine compounds | |
| AU2003249484A1 (en) | Novel bio-active molecules | |
| DK1725536T3 (da) | Imidazolin-derivater med CB1-antagonistisk aktivitet | |
| NO20082226L (no) | 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav | |
| ZA200500436B (en) | 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors | |
| HRP20070286T3 (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
| DE60213087D1 (de) | Pyrimidin-derivate als selektive inhibitoren von cox-2 | |
| MXPA04003278A (es) | Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina. | |
| EA200400470A1 (ru) | Замещенные производные алкиламинопиридазинона, способ их получения и содержащие их фармацевтические композиции | |
| PT1628968E (pt) | Compostos de 4-imidazolin-2-ona | |
| BR0307424A (pt) | Compostos heterocìclicos com atividade inibidora de elastase e seus intermediários | |
| EA200401099A1 (ru) | Производные гетероциклического амида | |
| ATE238300T1 (de) | (3,4-dihydro-2h-benzo(1,4)oxazinyl-methyl)-3-(1 - indol-3-yl)-alkylamine | |
| DK1756066T3 (da) | Tetrasubstituerede imidazolderivater som canabinoid-CB1-receptormodulatorer med höj CB1/CB2-receptorundertypeselektivitet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1668002 Country of ref document: EP |